Abstract | OBJECTIVE: METHODS:
TNF-alpha molecular expression and extracellular release were assessed in the peripheral blood mononuclear cells (PBMC) of 27 RA patients and 16 healthy blood donor controls during 8 hours of LPS stimulation. We also analyzed the mRNA expression of tristetraprolin ( TTP), the major TNF-alpha mRNA destabilizing factor. TNF receptor p75 (TNFR 2) plasma concentrations were also tested in all patients. RESULTS: Controls and patients demonstrated a comparable wide range of TNF-alpha release capability, but patients achieved the peak value of protein release more quickly. Defining the median TNF-alpha release in controls as the cutoff value to distinguish high and low LPS-induced TNF-alpha-releasing phenotypes, patients with early RA (disease duration < 1 yr) belonged mainly to the low TNF-alpha producer subgroup, whereas patients with long-standing RA (> 1 yr) were prevalently high TNF-alpha producers. TTP molecular expression was higher in patients with shorter, than in patients with longer, disease duration. The profile of TNF-alpha release in patients with early RA changed significantly when retested after 6 months of therapy, while patients with long-standing disease maintained the same behavior as at baseline. Finally, a baseline low TNF-alpha-producer phenotype predisposed to a better responsiveness to disease modifying antirheumatic drugs. CONCLUSION: The LPS-induced TNF-alpha-releasing phenotype differs between cells obtained from RA patients with different disease durations and seems to influence the therapeutic outcome.
|
Authors | Martina Fabris, Barbara Tolusso, Emma Di Poi, Paola Tomietto, Stefania Sacco, Elisa Gremese, Gianfranco Ferraccioli |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 32
Issue 6
Pg. 998-1005
(Jun 2005)
ISSN: 0315-162X [Print] Canada |
PMID | 15940758
(Publication Type: Journal Article)
|
Chemical References |
- Antirheumatic Agents
- DNA-Binding Proteins
- Immediate-Early Proteins
- Lipopolysaccharides
- RNA, Messenger
- Receptors, Tumor Necrosis Factor, Type II
- Tristetraprolin
- Tumor Necrosis Factor-alpha
- ZFP36 protein, human
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(immunology)
- Cells, Cultured
- DNA-Binding Proteins
(biosynthesis, genetics)
- Female
- Gene Expression
- Humans
- Immediate-Early Proteins
(biosynthesis, genetics)
- Leukocytes, Mononuclear
(drug effects, immunology)
- Lipopolysaccharides
(pharmacology)
- Male
- Middle Aged
- Prognosis
- RNA, Messenger
(metabolism)
- Receptors, Tumor Necrosis Factor, Type II
(blood, metabolism)
- Time Factors
- Tristetraprolin
- Tumor Necrosis Factor-alpha
(biosynthesis, genetics)
- Zinc Fingers
(genetics)
|